BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 30203114)

  • 1. Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.
    Cai B; Sun S; Li Z; Zhang X; Ke Y; Yang J; Li X
    Hum Genet; 2018 Sep; 137(9):679-688. PubMed ID: 30203114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced Pluripotent Stem Cells and Genome-Editing Tools in Determining Gene Function and Therapy for Inherited Retinal Disorders.
    Benati D; Leung A; Perdigao P; Toulis V; van der Spuy J; Recchia A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
    Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
    Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of CRISPR/Cas9 in retinal degenerative diseases.
    Peng YQ; Tang LS; Yoshida S; Zhou YD
    Int J Ophthalmol; 2017; 10(4):646-651. PubMed ID: 28503441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.
    Burnight ER; Giacalone JC; Cooke JA; Thompson JR; Bohrer LR; Chirco KR; Drack AV; Fingert JH; Worthington KS; Wiley LA; Mullins RF; Stone EM; Tucker BA
    Prog Retin Eye Res; 2018 Jul; 65():28-49. PubMed ID: 29578069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases.
    Wiley LA; Burnight ER; Songstad AE; Drack AV; Mullins RF; Stone EM; Tucker BA
    Prog Retin Eye Res; 2015 Jan; 44():15-35. PubMed ID: 25448922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized therapeutic strategies for patients with retinitis pigmentosa.
    Zheng A; Li Y; Tsang SH
    Expert Opin Biol Ther; 2015 Mar; 15(3):391-402. PubMed ID: 25613576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research progress of CRISPR-Cas9 system for gene therapy].
    Zhan C; Xia X
    Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells.
    Bassuk AG; Zheng A; Li Y; Tsang SH; Mahajan VB
    Sci Rep; 2016 Jan; 6():19969. PubMed ID: 26814166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa.
    Hu S; Du J; Chen N; Jia R; Zhang J; Liu X; Yang L
    Invest Ophthalmol Vis Sci; 2020 Apr; 61(4):31. PubMed ID: 32330228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Genome Editing by CRISPR/Cas9-Mediated Strategy to Cure Genetic Disorders in Humans: Guide for Molecular Surgeons.
    Ergoren MC; Idlibi R
    Crit Rev Eukaryot Gene Expr; 2019; 29(5):387-399. PubMed ID: 32421996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 genome surgery for retinal diseases.
    Xu CL; Park KS; Tsang SH
    Drug Discov Today Technol; 2018 Aug; 28():23-32. PubMed ID: 30205877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome Surgery and Gene Therapy in Retinal Disorders.
    Chan L; Mahajan VB; Tsang SH
    Yale J Biol Med; 2017 Dec; 90(4):523-532. PubMed ID: 29259518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene editing prospects for treating inherited retinal diseases.
    Benati D; Patrizi C; Recchia A
    J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.